Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Astellas closes stem cell unit’s Seattle site, layoffs incoming
Astellas is preparing to close its Seattle site for its stem cell therapy unit, with around 55 employees set to be affected.
James Waldron
Apr 14, 2026 10:45am
Lilly buys ADC specialist CrossBridge Bio in vague $300M deal
Apr 14, 2026 8:00am
ASGH 2026: Solving the Biotech Commercialisation Puzzle
Brought to you by
Asia Summit on Global Health (ASGH)
Boehringer, Amgen scrap immunology assets, citing low potential
Apr 14, 2026 4:00am
Beyond the Hype: Turning NAMs into Actionable Evidence
Brought to you by
Battelle
Takeda ends mRNA research pact with Japanese drug discoverer
Apr 14, 2026 9:57am
More News
Obsidian leverages Galera reverse merger to go public
Apr 14, 2026 11:20am
Click cuts staff after commercial deal restructuring
Apr 14, 2026 10:25am
Fierce Pharma
Novo becomes latest drugmaker to strike OpenAI pact
Apr 14, 2026 10:13am
Kazia pays research institute $1.4M for epigenetic platform
Apr 14, 2026 10:04am
See more stories
